Aveanna Healthcare Holdings Inc.

Aveanna Healthcare Holdings Inc. (AVAH) Market Cap

Aveanna Healthcare Holdings Inc. has a market capitalization of $1.70B.

Price: $7.79

0.25 (3.32%)

Market Cap: 1.70B

NASDAQ · time unavailable

CEO: Jeffrey S. Shaner

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2021-04-28

Website: https://www.aveanna.com

Aveanna Healthcare Holdings Inc. (AVAH) - Company Information

Market Cap: 1.70B|Sector: Healthcare

Company Profile

Aveanna Healthcare Holdings Inc. operates as a diverse platform for home-based care services throughout the United States. The company delivers a range of critical offerings, including private duty nursing (PDN), adult home health and hospice care, in-home pediatric therapy, and enteral nutrition services. Its patient-centered approach allows individuals to receive essential medical care within their own homes, effectively reducing the need for costly institutional settings such as hospitals. The company's operations are structured into three key segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment provides specialized private duty nursing, which includes skilled nursing care for medically fragile children at home, nursing support in school environments, and services at pediatric day healthcare centers. This segment also offers employer-of-record support, personal care services, and pediatric therapy (physical, occupational, and speech) provided both in clinics and patients' residences. The HHH segment focuses on home health services, encompassing in-home skilled nursing, physical, occupational, and speech therapy, as well as medical social work and aide assistance. Furthermore, it delivers hospice services, offering compassionate care to patients and their families when life-limiting illnesses no longer respond to curative treatments. The MS segment supplies enteral nutrition products and other vital medical supplies to adults and children, distributed on either a scheduled or as-needed basis. Founded in 2016, Aveanna Healthcare Holdings Inc. is headquartered in Atlanta, Georgia.

Analyst Sentiment

77%
Strong Buy

From 12 Active Polls

1Y Forecast: $10.00

▲ +28.4% Potential Upside

Consensus Target Metrics

Low Bound

$9

Median

$10

High Bound

$11

Average

$10

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$10.00
▲ +28.37% Upside
Low Target
$9.00
16% Risk
Median Target
$10.00
28% Mid
High Target
$11.00
41% Max
Consensus
Buy
7 / 12 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MApr 4, 2026Jan 3, 2026Sep 27, 2025Jun 28, 2025Mar 29, 2025Dec 28, 2024Sep 28, 2024Jun 29, 2024
Market Cap ($M)1,6961,3691,6441,8281,0091,0459011,000532
Enterprise Value ($M)3,0092,6822,9663,0272,3992,2982,1502,2541,819
Price to Earnings Ratio (P/E)6.398.222.3032.509.3350.337.72-5.839.56
Price/Earnings-to-Growth Ratio (PEG)0.355.921.726.653.62-7.253.28
Price to Sales Ratio (P/S)0.672.112.482.941.711.871.731.961.05
Price to Book Ratio (P/B)6.965.708.46184.42-89.58-10.59-7.38-6.45-4.52
Price to Free Cash Flow Ratio (P/FCF)12.42-6582.2929.7858.6320.00-95.2175.8736.78984.40
Enterprise Value to Sales (EV/Sales)4.144.484.874.074.114.144.433.60
Enterprise Value to EBITDA (EV/EBITDA)10.0632.8039.7654.3827.5444.3730.47117.0435.62
Debt to Equity Ratio4.396.267.79135.67-132.41-13.42-10.92-8.60-11.36
⚠️

Valuation Model Suspended

API Payload Error: Inverted or negative baseline Free Cash Flow margin detected (-2.3%).

Troubleshooting Notice: The upstream financial data supplier has uploaded corrupted or inverted baseline metrics for AVAH. The server sandbox cannot calculate an intrinsic value path from negative cash generation baselines.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 AVEANNA HEALTHCARE HOLDINGS INC (AVAH) — Investment Overview

🧩 Business Model Overview

Aveanna provides home-based healthcare services, with a focus on medically complex patients—particularly pediatric and long-duration care settings. The operating model is built around creating and maintaining clinical capacity (licensed clinicians, therapists, and care coordination teams), matching that capacity to patient needs, and billing payors (primarily government programs and managed care) for skilled and non-skilled services delivered in the home.

Value creation occurs through (1) care delivery infrastructure that supports ongoing patient needs, (2) operational scheduling and documentation that sustains reimbursement, and (3) referral and payor contracting relationships that enable patient inflows and continuity of care. This is a “service-and-coverage” business: patient retention and caregiver availability drive results more than single-service transactions.

💰 Revenue Streams & Monetisation Model

Revenue is largely driven by recurring service hours and reimbursable care episodes, including:

  • Skilled and personal care services billed by visit, service hour, or episode depending on program requirements.
  • Therapy and ancillary services (where applicable) that support patient care plans and improve utilization of clinical coverage.
  • Private-pay and managed care contributions that may partially offset government reimbursement variability.

Monetisation is therefore operationally linked to:

  • Patient census and acuity (a key driver of service intensity).
  • Care-plan adherence and documentation quality (reimbursement eligibility and audit outcomes).
  • Labor productivity (utilization, travel/time management, and scheduling efficiency).

Margin performance typically hinges on the cost discipline of staffing and overhead relative to reimbursement rates, plus the ability to sustain compliant billing under payer and regulatory standards.

🧠 Competitive Advantages & Market Positioning

Aveanna operates in a fragmented, provider-led home healthcare landscape where scale and compliance matter. The most durable competitive advantages are less about proprietary technology and more about the operational and regulatory “barriers to serving patients reliably.”

Primary moats:

  • High switching costs (patient- and plan-level): For medically complex patients, continuity of clinical staff, care routines, and caregiver availability creates practical inertia. Care transitions can be disruptive to patient outcomes and are constrained by reimbursement approval timelines.
  • Regulatory and administrative barriers: Home healthcare requires licensure, agency certification, and sustained compliance with payer documentation and quality expectations (audit and recertification risk raise the cost of entry and the cost of sloppy execution).
  • Integrated care delivery ecosystem: Coordinated clinical staffing, scheduling, and documentation systems function as an execution moat—competitors can replicate offerings, but duplicating performance across multiple regions requires time, talent, and compliance maturity.

Competitive benchmarking (industry comparables):

  • LHC Group and Enhabit (large home health and hospice operators): these peers compete on geographic coverage, care-team density, and contract execution across payer mix. Aveanna’s focus on pediatric and medically complex home care can lead to a different patient-acuity and care-delivery profile than broader home health and hospice mixes.
  • BAYADA Home Health Care (private-duty and home health): BAYADA competes heavily on caregiver staffing and case management. Aveanna’s positioning emphasizes pediatric/long-duration home services, which can support stickier care plans but also demands strong staffing and compliance capabilities.

Against these rivals, Aveanna’s industry focus tilts toward higher complexity and longer-duration home care, where operational reliability, caregiver availability, and documentation discipline are primary differentiators.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by structural demand and by service mix shifts rather than a single-product cycle:

  • Shift from institutional settings to home-based care: Policy incentives and cost-management pressures favor care delivery outside hospitals and nursing facilities where clinically appropriate.
  • Rising prevalence of chronic and medically complex conditions: Longer survival and increasing acuity expand home care need, supporting sustained service intensity.
  • Care coordination and value-based contracting opportunities: Managed care programs increasingly reward outcomes and efficient utilization, benefiting providers with disciplined documentation, care management, and operational execution.
  • Contracting and payer penetration: Geographic and payer coverage can compound through referral networks and negotiated reimbursement frameworks, subject to compliance and staffing constraints.

For this business model, growth durable advantages depend on maintaining compliant billing, reducing labor inefficiencies, and sustaining caregiver capacity as patient volumes expand.

⚠ Risk Factors to Monitor

  • Reimbursement risk and payer contract uncertainty: Government program reimbursement policies and managed care contract terms can pressure revenue per visit/hour, even when patient demand remains stable.
  • Regulatory and compliance exposure: Documentation errors, coding practices, or quality lapses can trigger denials, audits, repayment obligations, or certification issues.
  • Workforce availability and wage inflation: Home health is labor-dependent. Staffing shortages, turnover, and wage pressure can compress margins and impair care continuity.
  • Concentration of patient acuity and operational execution: Higher acuity cases increase the importance of scheduling accuracy, clinician coverage, and clinical oversight.
  • Litigation and HIPAA/cyber risk: Healthcare providers face heightened exposure from care delivery disputes and information security requirements.

📊 Valuation & Market View

Equity valuation for home healthcare operators typically centers on cash-generating operational performance rather than growth-only narratives. Markets often reference EV/EBITDA and P/S frameworks, with premium multiples usually tied to:

  • Stability and visibility of margins (labor efficiency and compliant reimbursement).
  • Demonstrated operating leverage as patient volumes scale.
  • Quality metrics and audit outcomes that reduce downside risk from denials and repayment.
  • Cash conversion and working capital discipline (home health reimbursement timing can affect cash flow patterns).

As a service-heavy healthcare model, multiple expansion is generally more achievable when execution improves on staffing productivity, reimbursement capture, and operating leverage—rather than from one-off growth catalysts.

🔍 Investment Takeaway

Aveanna’s long-term case rests on durable execution moats in home-based care: practical switching costs from care continuity needs, regulatory and administrative barriers that raise the entry threshold, and an integrated clinical delivery ecosystem that supports sustained service provision for medically complex patients. The primary debate for investors is the balance between demand tailwinds and the ongoing ability to manage labor, compliance, and payer reimbursement pressure while expanding care coverage profitably.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for AVAH.

zacks.com2026-06-10

AVAH or CHE: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Aveanna Healthcare (AVAH) and Chemed (CHE). But which of these two stocks presents investors with the better value opportunity right now?

zacks.com2026-06-09

Best Cheap Stocks Under $10 to Buy Now in June Amid the Market Selloff

Bullish investors who want to start buying into market weakness might consider adding highly-ranked cheap stocks trading under $10 per share.

zacks.com2026-06-09

4 Outpatient Home Health Stocks Benefiting From Industry Trends

An aging population and rising telehealth and AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, LFST and AVAH stand to benefit.

marketbeat.com2026-06-02

Aveanna Healthcare Raises 2026 Outlook After Family First Deal, Eyes 7%-10% Growth

Aveanna Healthcare NASDAQ: AVAH executives outlined the company's growth strategy, updated 2026 guidance and discussed its newly closed Family First Homecare acquisition during a presentation at William Blair's Growth Stock Conference.

zacks.com2026-06-02

Wall Street Analysts Predict a 50.67% Upside in Aveanna (AVAH): Here's What You Should Know

The consensus price target hints at a 50.7% upside potential for Aveanna (AVAH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

globenewswire.com2026-06-02

Aveanna Healthcare Holdings Completes Acquisition of Family First Homecare and Updates Full Year 2026 Guidance

ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced that it completed its acquisition of Family First Holding, LLC ("Family First Homecare").

globenewswire.com2026-05-28

Aveanna Healthcare Announces Successful Debt Repricing

ATLANTA, May 28, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (Nasdaq: AVAH), a leading, diversified home care platform focusing on providing care to medically complex, high-cost patient populations, today announced the repricing of its first lien credit facility and revolving credit facility. The repriced credit facilities provide for a 50 basis point reduction to applicable interest rate margins, as well as an additional reduction of 25 basis points to the applicable margins upon the Borrower obtaining a rating of at least B2 or B from certain credit rating agencies.

zacks.com2026-05-25

AVAH vs. CHE: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Aveanna Healthcare (AVAH) or Chemed (CHE). But which of these two stocks is more attractive to value investors?

seekingalpha.com2026-05-19

Aveanna Healthcare: Q1 Results Confirm My Reasons For Optimism

Aveanna Healthcare Holdings reported strong Q1 2026 results, with EPS and revenue significantly beating expectations and shares rising 14% post-earnings. Q1 2026 was the ninth straight quarter in which AVAH has beaten analysts' earnings expectations and the 14th in which it has topped revenue estimates. Key risks include high debt levels, negative free cash flow in Q1 2026, and insider selling, but AVAH's forward PE of 11.4 and PEG ratio of 0.77 support continued upside.

seekingalpha.com2026-05-14

Aveanna Healthcare Holdings Inc. (AVAH) Q1 2026 Earnings Call Transcript

Aveanna Healthcare Holdings Inc. (AVAH) Q1 2026 Earnings Call Transcript

marketbeat.com2026-05-14

Aveanna Healthcare Q1 Earnings Call Highlights

Aveanna Healthcare NASDAQ: AVAH raised its full-year 2026 outlook after reporting double-digit revenue and adjusted EBITDA growth in the first quarter, citing improved reimbursement rates, higher volumes and operating efficiencies across its three business segments.

zacks.com2026-05-14

Compared to Estimates, Aveanna (AVAH) Q1 Earnings: A Look at Key Metrics

The headline numbers for Aveanna (AVAH) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com2026-05-14

Aveanna Healthcare (AVAH) Tops Q1 Earnings and Revenue Estimates

Aveanna Healthcare (AVAH) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.1 per share a year ago.

globenewswire.com2026-05-14

Aveanna Healthcare Holdings Announces First Quarter Financial Results and Revised 2026 Guidance

First Quarter Revenue was $647.9 million, a 15.9% increase over the prior year period First Quarter Net income was $41.7 million compared to $5.2 million for the prior year period Adjusted EBITDA for Q1 2026 was $84.4 million, a 25.2% increase over the prior year period Increased Full Year 2026 Revenue guidance to between $2.56 and $2.58 billion, updated from between $2.54 and $2.56 billion Increased Full Year 2026 Adjusted EBITDA guidance to between $328 and $332 million, updated from between $318 and $322 million ATLANTA, May 14, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three-month period ended April 4, 2026. Jeff Shaner, Chief Executive Officer, commented, “Q1 reflects the strength and resiliency of our business model with an impressive start to 2026.

globenewswire.com2026-05-12

Aveanna to Participate at the William Blair 46th Annual Growth Stock Conference

ATLANTA, May 12, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the William Blair 46th Annual Growth Stock Conference in Chicago on June 2, 2026. Management will present at 2:40pm CST and will also host 1x1 investor meetings that same day. Interested investors and other parties may also listen to a simultaneous webcast of the presentation by logging onto the Investor Relations section of the Company's website at https://ir.aveanna.com/. The online replay will be available for a limited time shortly following the call.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-04-04

"AVAH (Q1 2026, reported 2026-04-04) delivered Revenue of $647.9M and Net Income of $41.7M (EPS $0.19). YoY, Revenue increased 15.8% versus Q1 2025 ($559.2M), and Net Income jumped from $5.2M to $41.7M (+703.6%). QoQ, Revenue declined 2.2% versus Q4 2025 ($662.5M), while Net Income rose 76.9% (from $17.9M). Profitability is improving: gross margin was 31.2% (slightly down QoQ from 31.8% but up vs 32.8% in Q1’25), and net margin improved sharply to 6.4% from 27.0% in Q4’25 (one-quarter distortion) and from 0.9% in Q1’25—indicating a major earnings inflection vs last year. Cash flow quality is mixed. Operating cash flow was a modest $4.3M, down from $49.7M in Q4’25, with working capital changes turning cash outflow in the quarter. Free cash flow was -$0.2M (vs +$55.2M in Q4’25), suggesting near-term cash generation pressure despite stronger accounting earnings. Balance sheet resilience looks challenged: total assets ~$2.02B are down slightly QoQ, but leverage remains high (net debt ~$1.31B; equity $240.1M vs $194.5M QoQ). No dividends were paid. Total shareholder returns look strong: the stock is up 48.5% over 1 year, which should support a higher “momentum/returns” score alongside the improved YoY earnings."

Revenue Growth

Positive

YoY Revenue +15.8% (Q1’25 $559.2M → Q1’26 $647.9M). QoQ Revenue -2.2% ($662.5M in Q4’25 → $647.9M).

Profitability

Positive

Net Income YoY +703.6% ($5.2M → $41.7M). QoQ Net Income +76.9% ($17.9M → $41.7M). Margins: net margin 6.4% vs 0.9% YoY, though it fell from an unusually high Q4’25 net margin (27.0%), implying volatility.

Cash Flow Quality

Caution

Operating cash flow was only $4.3M in Q1’26 vs $49.7M in Q4’25. Free cash flow was -$0.2M vs +$55.2M QoQ, indicating weaker cash conversion despite earnings improvement.

Leverage & Balance Sheet

Fair

High leverage persists: net debt ~$1.31B and total equity only ~$240M. Total assets slightly down QoQ (~$2.03B → $2.02B) but debt remains elevated (short-term + long-term debt).

Shareholder Returns

Positive

1-year price change +48.5% (strong momentum). No dividends. Buybacks not evident in Q1’26 (common repurchased $0), but total return is likely supported by the strong price appreciation.

Analyst Sentiment & Valuation

Fair

Consensus price target $11 vs current price $6.77 implies meaningful upside on paper. However, cash flow volatility and high leverage temper quality of the outlook.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Aveanna delivered a strong Q1 2026 rebound driven by a preferred-payer-led operating model across PDS, Home Health & Hospice, and Medical Solutions. Revenue rose 15.9% to ~$647.9M and adjusted EBITDA jumped 25.2% to $84.4M, with margin strength supported by improved rate/volume and operational efficiencies. The most actionable clarifications from Q&A were: (1) CMS’s home health & hospice moratorium was assessed by management as “0 impact” on Aveanna and the pending Family First deal (guidance explicitly unaffected), (2) earnings cadence was influenced by timing collections from previously reserved AR (~$6M) and weather-related revenue loss (~$5.5M–$6M; ~ $1.5M EBITDA impact), and (3) PDS upside is expected to be mostly volume-driven as rate/wage has “basically settled,” implying limited wage/price spread expansion beyond small percentage moves. Guidance increased for FY2026 (ex-Family First): revenue $2.56B–$2.58B and adj. EBITDA $328M–$332M.

AI IconGrowth Catalysts

  • Private Duty Services (PDS) caregiver hiring/retention improvement tied to preferred payer wage and value-based agreements; Q1 PDS revenue up 16.4% with hours +10.7% and revenue per hour +5.7%
  • Home Health & Hospice episodic mix at ~80% (goal >75%) with admissions ~11,000 (+13.4% organic) and episodes +23.1%, supporting gross margin of 53.7%
  • Medical Solutions preferred payer modernization/rollout contributing to 93,000 unique patients and UPS +2.9% (revenue +7.4%), with management expecting margin normalization and growth acceleration in back half of 2026

Business Development

  • Family First Homecare acquisition (Florida-based pediatric home care); regulatory approval in progress; management expects close in late Q2
  • Thrive Skilled Pediatrics referenced as another acquisition integration/strategic growth platform alongside Family First
  • Alliance National Alliance of Care at Home referenced as an industry group to coordinate with Dr. Oz/CMS on targeted enforcement (e.g., fraud/waste/abuse areas)

AI IconFinancial Highlights

  • Revenue: ~$647.9M (+15.9% YoY) versus prior year period
  • Adjusted EBITDA: $84.4M (+25.2% YoY) driven by improved rate/volume environment and operational efficiencies
  • Consolidated gross margin: $205.4M (31.7%)
  • PDS gross margin: $149.2M (27.9%); spread per hour $12.38; Q1 revenue per hour $44.43 (+5.7% YoY)
  • Home Health & Hospice: Medicare revenue per episode $3,167 (+0.5% YoY); Q1 gross margin 53.7%
  • Medical Solutions: gross margin ~$20.4M (44.7%); revenue per UPS ~$491 (+2.9% YoY)
  • One-time/timing cash collection items: strong Q1 collections on previously reserved AR ~ $6M, impacting both revenue and EBITDA in-quarter
  • Weather impacts: two major January weather events; management cited ~$5.5M–$6M revenue lost over two weeks, equating to ~ $1.5M EBITDA impact; Q1 results were supported by timing-related collections that otherwise would have landed in the high-70% EBITDA landing zone (qualitative range)

AI IconCapital Funding

  • Liquidity: ~$525M total (cash ~$189M; securitization facility availability ~$110M; revolver availability ~$226M and undrawn)
  • Letters of credit outstanding: ~$24.5M
  • Variable rate debt: ~$1.48B (of which $520M hedged with fixed rate swaps; $880M subject to an interest rate cap limiting exposure to increases in SOFR above 3%)
  • Interest rate caps/swaps coverage: swaps extend through June 2026; caps extend through February 2027; additional interest rate cap effective July 2026 limiting exposure on $520M of variable debt to increases in SOFR above 4% through December 2029
  • Cash flow: operating cash flow $4.3M; free cash flow negative $3.8M (Q1 seasonal low point stated by management)

AI IconStrategy & Ops

  • Preferred payer strategy as core operating lever across PDS, Home Health & Hospice, and Med Solutions to improve staffing/hiring and stabilize margins
  • Automation/AI focus in RCM: management stated AI/automation reduced DSO and improved cash collections, shifting capacity toward collecting aged AR previously considered uncollectible
  • Expense discipline/SG&A leverage: management credited minimal overhead additions despite organic growth to automation in scheduling and RCM
  • Regulatory and acquisition operations: Family First deal progressing through approval; guidance explicitly excludes acquisition impact pending close

AI IconMarket Outlook

  • 2026 guidance (excluding Family First acquisition): revenue $2.56B–$2.58B; adjusted EBITDA $328M–$332M
  • PDS 2026 rate environment: management expects mid-single-digit state rate enhancements in 2026 and cited receiving 3 PDS state rate wins as of Q1; goal aligns with states completing annual budgets
  • PDS preferred payers target: 8 additional agreements for total 38 preferred payers in 2026; signed 4 in Q1; Q1 preferred payer MCO volumes ~60% of total PDS MCO volumes (up from 57% end of 2025)
  • Home Health episodic mix target: maintain episodic payer mix >75%; Q1 episodic mix ~80%; total episodic volume growth +23.1%; home health preferred payers target 50 in 2026; exited 2025 with 45 and added 4 in Q1
  • Medical Solutions preferred payer target: expected to grow from 18 preferred payers at end of 2025 to 25 by end of 2026; Q1 signed 2 to reach 20 total

AI IconRisks & Headwinds

  • Labor environment remained a primary historical challenge; management highlights demand is strong but caregiver availability depends on reimbursement alignment with preferred payers
  • Regulatory headwinds: CMS home health and hospice 6-month enrollment moratoria (Medicare licensure context) raised by analysts; management stated “0 impact” on Aveanna and Family First as read from Q&A and because 36-month rule has been in place for at least a decade
  • Collection/timing volatility risk: Q1 included positive ~ $6M reserved AR collection impact; weather events caused ~$5.5M–$6M revenue loss over two weeks (~$1.5M EBITDA impact)
  • Macro enforcement targeting: management requested industry focus on fraud/waste/abuse in specific areas (e.g., L.A. County) to avoid punishing rural providers needing more capacity
  • Interest rate risk: although largely hedged, further SOFR increases are bounded by caps (details provided); risk persists around cap structure expirations and transition to new cap effective July 2026

Q&A: Analyst Interest

  • Topic: CMS home health & hospice 6-month enrollment moratoria—impact on Aveanna/M&A and Medicare licensure transfer. Management: stated it has absolutely 0 impact on Aveanna and Family First on its reading, reaffirmed the 36-month rule for targeted acquisitions is longstanding, and expects no change to 2026/2027 guidance or M&A ability; they want targeted enforcement (e.g., L.A. County).
  • Topic: Q1 cash flow and earnings cadence—one-time AR timing, AI/automation effects, and Q2 seasonality build. Management: attributed improved Q1 to AI/automation in RCM reducing DSO and enabling collection of previously reserved aged AR (~$6M reserve released in quarter). They said Q1 is usually the lowest EBITDA quarter, but Q1 was ~$5M–$6M stronger than expected; build to Q2 is typically less than normal yet still strong.
  • Topic: PDS economics vs wage pass-through and preferred payer penetration—pricing vs volume drivers. Management: indicated PDS rate/wage is mostly settled with limited movement (about 1–2 percentage points, not $0.50–$1 per hour). They expect preferred payer wins to drive primarily volume rather than significant incremental pricing; spread should remain in low-$12 range moving forward.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the AVAH Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for AVAH.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (AVAH)

© 2026 Stock Market Info — Aveanna Healthcare Holdings Inc. (AVAH) Financial Profile